How Microbes Affect Depression: Underlying Mechanisms via the Gut-Brain Axis and the Modulating Role of Probiotics
- PMID: 35163104
- PMCID: PMC8835211
- DOI: 10.3390/ijms23031172
How Microbes Affect Depression: Underlying Mechanisms via the Gut-Brain Axis and the Modulating Role of Probiotics
Abstract
Accumulating evidence suggests that the gut microbiome influences the brain functions and psychological state of its host via the gut-brain axis, and gut dysbiosis has been linked to several mental illnesses, including major depressive disorder (MDD). Animal experiments have shown that a depletion of the gut microbiota leads to behavioral changes, and is associated with pathological changes, including abnormal stress response and impaired adult neurogenesis. Short-chain fatty acids such as butyrate are known to contribute to the up-regulation of brain-derived neurotrophic factor (BDNF), and gut dysbiosis causes decreased levels of BDNF, which could affect neuronal development and synaptic plasticity. Increased gut permeability causes an influx of gut microbial components such as lipopolysaccharides, and the resultant systemic inflammation may lead to neuroinflammation in the central nervous system. In light of the fact that gut microbial factors contribute to the initiation and exacerbation of depressive symptoms, this review summarizes the current understanding of the molecular mechanisms involved in MDD onset, and discusses the therapeutic potential of probiotics, including butyrate-producing bacteria, which can mediate the microbiota-gut-brain axis.
Keywords: depression; gut microbiome; gut–brain axis; probiotics.
Conflict of interest statement
K.S. and K.M. are employees of Yakult Honsha Co., Ltd., Tokyo, Japan.
Figures
References
-
- World Health Organization. [(accessed on 3 December 2021)]. Available online: https://www.who.int/en/news-room/fact-sheets/detail/depression.
-
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7. - DOI - PMC - PubMed
-
- Owens M.J. Selectivity of antidepressants: From the monoamine hypothesis of depression to the SSRI revolution and beyond. J. Clin. Psychiatry. 2004;65:5–10. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources